Recent Updates
Recently added Catalysts
JAZZ Neutral Sentiment

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025,...

Key Takeaway: Jazz Pharmaceuticals announced it will report its second quarter financial results for 2025 on August 5, 2025. The results will be disclosed after the U.S. financial markets close, followed by a live audio webcast hosted by company management. Participants are encouraged to register in advance for the webcast, which will also have a replay available later on their investor website. The company emphasizes its commitment to developing innovative treatments in various therapeutic areas.
Price reaction · baseline $112.65 (2025-07-21 close) · hit after-hours · clean, no other JAZZ news in the window
day 0 close · peak
+3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Company will provide a financial update, showing transparency.
  • Management's engagement through a live audio webcast.
  • Reputation for innovating life-changing medicines.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
2.1%
average across 9 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2

Full Press Release Details

DUBLIN , July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter financial results and provide a business and financial update.
Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Frequently Asked Questions

When will Jazz Pharmaceuticals report its Q2 2025 results?

Jazz Pharmaceuticals will report its Q2 2025 results on August 5, 2025.

What time is the financial results webcast scheduled?

The webcast is scheduled for 4:30 p.m. EDT / 9:30 p.m. IST.

Where can I register for the Jazz Pharmaceuticals call?

Registration can be done via the Investors section on Jazz’s website.

Will the financial results webcast be available later?

Yes, a replay will be available on the Investors section of their website.

What is the focus of Jazz Pharmaceuticals' research?

Jazz specializes in medicines for serious diseases with limited treatment options.

Last updated: Jul 22, 2025